Sumgen Mab (beijing) Biotech Co., Ltd.

Hangzhou Sumgen Biotech Co., Ltd.

Sumgen Mab Biotech Co., Ltd.

Bin Tan

Ming Lv

Shiwei Miao

Xiaoran Ding

Xuegong Wang

Provided is a fusion protein, comprising a first binding domain that specifically binds a tumor-associated antigen, and a second binding domain that specifically binds a CD47 protein, wherein the second binding domain comprises a mutant of a human SIRPα variant 1. Also provided are an immunoconjugate, nucleic acid molecules, vectors, compositions, and cells related to the fusion protein and preparation methods therefor, and the uses thereof in the preparation of medicaments.

Fusion protein and use thereof

Provided is an antibody or an antigen-binding fragment thereof, having one or more properties selected from the group consisting of: 1) being capable of binding to an AXL protein by a Kvalue of 1×10M or lower; 2) being capable of specifically recognizing an AXL protein expressed on a cell surface; and 3) being capable of mediating internalization after binding to the AXL protein expressed on the cell surface. The antibody may further used for constructing an immunoconjugate. The antibody and the immunoconjugate may inhibit the proliferation of tumor cells.

Antibody binding to AXL protein and application thereof

Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRPα without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.

Fusion protein binding to CD47 protein and application thereof

Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a Kvalue below 1&#xd7;10-M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.

Growing community of inventors

Zhejiang, China

Bin Tan